The Institute for Clinical and Economic Review says new acute migraine medications aren’t worth their cost. Here’s how the economists got it wrong.
How ICER’s Evidence Report Fails Migraine Patients
Menu
The Institute for Clinical and Economic Review says new acute migraine medications aren’t worth their cost. Here’s how the economists got it wrong.
© 2024, Alliance for Patient Access.